Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Nivolumab / ipilimumab for untreated metastatic non-small-cell lung cancer as of September 2021

MARA Rating Company December 16, 2025

Nivolumab / opdivo for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy as of October 2021

MARA Rating Company December 16, 2025

Nivolumab / opdivo for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer as of November 2021

MARA Rating Company December 16, 2025

Nivolumab / ipilimumab for untreated advanced renal cell carcinoma as of March 2022

MARA Rating Company December 16, 2025

Nivolumab / opdivo for adjuvant treatment of invasive urothelial cancer at high risk of recurrence as of August 2022

MARA Rating Company December 16, 2025

Latanoprost-netarsudil for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension as of October 2024

MARA Rating Company December 16, 2025

Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over as of July 2024

MARA Rating Company December 16, 2025

Revlimid / lenalidomide for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma as of March 2021

MARA Rating Company December 16, 2025

Lenvatinib / pembrolizumab for untreated advanced renal cell carcinoma in adults as of January 2023

MARA Rating Company December 16, 2025

Linzagolix for treating moderate to severe symptoms of uterine fibroids as of August 2024

MARA Rating Company December 16, 2025